IRTC

In April 2026, iRhythm reported Q1 2026 revenue of $199.4 million, a 25.7% year-over-year increase, and adjusted EBITDA of $14.1 million, also raising its full-year 2026 revenue guidance. In May 2026, the company commercially launched its Zio Long-Term ECG Monitoring System in Japan. A partnership with Lucem Health was formed in July 2026 to utilize predictive AI for earlier arrhythmia identification. On August 6, 2026, iRhythm announced Q2 2026 financial results, with revenue of $224.2 million (up 20.1% year-over-year), a narrowed GAAP net loss, and adjusted net income of $19.3 million, again raising its full-year 2026 revenue guidance to $880M-$890M and adjusted EBITDA margin outlook to 13%-14%. iRhythm entered into a definitive agreement to acquire VitalConnect for approximately $287.5 million, a deal expected to close by the end of 2026, which will broaden its cardiac monitoring portfolio and was funded from its balance sheet. The company also received FDA clearance for its third-generation algorithm. Analyst rating changes included Truist Financial raising its price target to $168, Needham & Company LLC increasing its price objective to $194, Wall Street Zen upgrading iRhythm to a 'buy,' Wells Fargo & Company lowering its price target to $150, and Weiss Ratings reiterating a 'sell' rating. The stock experienced a significant decline, hitting a 52-week low of $100.70 on October 8, 2026, falling approximately 9.27% over the past six months and about 40% over the last year.